Find a Physician | How to Contribute | About Us | Clinical Trials
Select a Cancer Type:
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Clinical Trial DRUG STML-701-0114

A Phase 1/2 Study of SL-701, a Subcutaneously Injected Multivalent Glioma-Associated Antigen Vaccine, in Adult Patients with Recurrent Glioblastoma Multiforme
Principal Investigator
Jeffrey Raizer
  • Status: Accepting New Patients
  • Study Type: Therapeutic, Treatment
  • Protocol No:.DRUG STML-701-0114
The goal of this research study is to establish the safety and tolerability of the drug SL-701, and to determine its effects on patients with recurrent Glioblastoma Multiforme (GBM) tumors.
SL-701 is an experimental medication. This means that the United States Food and Drug Administration (FDA) has not yet approved SL-701. SL-701 is an anti-cancer immunotherapy that uses 3 different short proteins, called “peptides,” that are found in certain brain tumors. The immunotherapy is designed to activate the immune system to recognize and kill brain-tumor cells that display proteins similar to the peptides in SL-701.
Some of the eligibility criteria include:
  • Participants must be 18 years of age or older.
  • Participants must have tumor recurrence (cancer came back) or progression (cancer is worsening)after initial (first) treatment.
  • Participants who received prior cancer chemotherapy with bevacizumab or other VEGF-VEGFR-directed agents (check with the study doctor for any exclusions) cannot participate in this study.
Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Description of Treatment
Participants will receive SL-701 as an injection (shot by needle) along with an additional medication that will make the immune response stronger. This additional medication (poly-ICLC) is referred to as an adjuvant. Participants will also receive bevacizumab (approved by the FDA for the treatment of GBM) in combination with SL-701 and poly-ICLC. To receive study treatment, participants will come to the study center two times per week for the first 2 weeks, every week for the next 2 weeks, and every 2 weeks thereafter through Week 22. After Week 22, participants will come to the clinic every 4 weeks to receive SL-701 and poly-ICLC injections. Bevacizumab will continue to be given every 2 weeks after Week 22.
Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center

Find Related Clinical Trials

Browse by Disease Sites

Other Clinical Trials by Jeffrey Raizer

last updated: 25-Nov-15 02:13 AM


Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.